Velpaget (sofosbuvir + velpatasvir): Uses, Dosage & Side Effects

What it's for (Indications)

Sofosbuvir + velpatasvir (e.
g.
, Abriva Plus) is a highly effective, pangenotypic direct-acting antiviral (DAA) medication specifically indicated for the treatment of chronic hepatitis C virus (HCV) infection.
This robust therapeutic agent is approved for use across all major HCV genotypes (1, 2, 3, 4, 5, and 6) in adults and pediatric patients 3 years of age and older.
Its indications encompass a broad range of patient populations, including those without cirrhosis, those with compensated cirrhosis, and patients with decompensated cirrhosis, where it is typically administered in combination with ribavirin.
Furthermore, it is a crucial treatment option for patients coinfected with human immunodeficiency virus (HIV) and HCV, offering a simplified and highly efficacious regimen to address this complex comorbidity.
The broad applicability of this medication streamlines treatment decisions and significantly improves sustained virologic response rates across diverse patient profiles.
It represents a cornerstone in the global effort to eradicate chronic HCV.

Dosage Information

Type	Guideline
Standard	For adult patients, the recommended oral dosage of sofosbuvir + velpatasvir is one tablet (containing 400 mg sofosbuvir and 100 mg velpatasvir) taken once daily, with or without food. The precise duration of treatment is contingent upon the patient's clinical characteristics, including their HCV genotype, the presence and severity of cirrhosis, and prior treatment history. For most patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), a 12-week course is typically prescribed. However, for patients with decompensated cirrhosis (Child-Pugh B or C), the recommended regimen involves 12 weeks of sofosbuvir + velpatasvir administered in combination with weight-based ribavirin. Pediatric dosing for patients 3 years of age and older is determined by weight, following specific guidelines to ensure appropriate exposure and efficacy. Adherence to the prescribed regimen is paramount to achieve optimal sustained virologic response (SVR) and minimize the risk of treatment failure and resistance development. Patients should be advised to take the medication at approximately the same time each day.

Type

Guideline

Standard

For adult patients, the recommended oral dosage of sofosbuvir + velpatasvir is one tablet (containing 400 mg sofosbuvir and 100 mg velpatasvir) taken once daily, with or without food. The precise duration of treatment is contingent upon the patient's clinical characteristics, including their HCV genotype, the presence and severity of cirrhosis, and prior treatment history. For most patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), a 12-week course is typically prescribed. However, for patients with decompensated cirrhosis (Child-Pugh B or C), the recommended regimen involves 12 weeks of sofosbuvir + velpatasvir administered in combination with weight-based ribavirin. Pediatric dosing for patients 3 years of age and older is determined by weight, following specific guidelines to ensure appropriate exposure and efficacy. Adherence to the prescribed regimen is paramount to achieve optimal sustained virologic response (SVR) and minimize the risk of treatment failure and resistance development. Patients should be advised to take the medication at approximately the same time each day.

Safety & Warnings

Common Side Effects

Sofosbuvir + velpatasvir generally exhibits a favorable safety profile; however, like all medications, it is associated with a spectrum of potential side effects.
The most commonly reported adverse reactions, occurring in a significant proportion of patients, include headache, which is often mild to moderate in intensity, and fatigue, which can range from mild lassitude to more pronounced weariness impacting daily activities.
Other frequent gastrointestinal complaints include nausea and diarrhea.
Insomnia is also reported by some patients.
Less common but potentially serious adverse effects necessitate clinical vigilance.
These include symptomatic bradycardia when co-administered with amiodarone, particularly in patients also receiving beta-blockers or with underlying cardiac conditions.
Furthermore, in patients with advanced liver disease, especially those with decompensated cirrhosis, there is a risk of liver decompensation or hepatic failure, particularly if the treatment is not carefully managed or if underlying factors exacerbate liver dysfunction.
The overall tolerability often allows for completion of the full treatment course.

Serious Warnings

Black Box Warning: **WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV** Direct-acting antiviral (DAA) medications for hepatitis C virus (HCV), including sofosbuvir + velpatasvir, carry a serious risk of reactivating hepatitis B virus (HBV) in patients who are coinfected with both HCV and HBV. HBV reactivation, which may manifest as fulminant hepatitis, liver failure, or even death, has been reported in patients undergoing or having completed HCV DAA treatment. **SCREENING AND MONITORING:** All patients should be screened for evidence of current or prior HBV infection before initiating treatment with sofosbuvir + velpatasvir. For patients with HBV/HCV coinfection, the risk of HBV reactivation should be discussed, and appropriate clinical monitoring for HBV flares or reactivation should be conducted during HCV treatment and post-treatment follow-up. This monitoring should include, at minimum, regular assessments of HBV viral load, liver function tests (e.g., ALT, AST, bilirubin), and clinical signs and symptoms of hepatitis. Management of HBV reactivation should be initiated as clinically indicated, potentially requiring antiviral therapy for HBV. The benefits of HCV treatment must be carefully weighed against the risk of HBV reactivation in these patients.
Several critical warnings are associated with the use of sofosbuvir + velpatasvir, requiring careful patient evaluation and monitoring.
A significant concern is the risk of severe symptomatic bradycardia and cardiac arrest when co-administered with amiodarone, particularly in patients also taking beta-blockers or with pre-existing cardiac comorbidities.
Co-administration of amiodarone is generally not recommended, and if unavoidable, cardiac monitoring in an inpatient setting for the first 48 hours, followed by outpatient or self-monitoring, is crucial.
Another paramount warning involves the risk of hepatitis B virus (HBV) reactivation in patients coinfected with both HCV and HBV.
This reactivation can lead to serious, life-threatening, or even fatal fulminant hepatitis.
All patients should be screened for HBV infection prior to initiating treatment, and those found to be HBV-positive should be monitored for HBV flares during and after treatment.
Moreover, patients with decompensated cirrhosis are at increased risk of liver decompensation and hepatic failure, necessitating close clinical and laboratory monitoring throughout and post-treatment.
Significant drug-drug interactions with strong P-glycoprotein (P-gp) inducers and/or moderate-to-strong CYP3A4 inducers can reduce drug concentrations and lead to treatment failure.

How it Works (Mechanism of Action)

Sofosbuvir + velpatasvir represents a synergistic combination of two distinct direct-acting antiviral agents, each targeting a crucial step in the hepatitis C virus (HCV) life cycle. Sofosbuvir is a nucleotide analog prodrug that undergoes intracellular metabolism to form an active uridine analog triphosphate. This active metabolite acts as a chain terminator, inhibiting the HCV NS5B RNA-dependent RNA polymerase. NS5B is an essential enzyme responsible for replicating the viral RNA genome, and its inhibition effectively halts viral replication. Velpatasvir, on the other hand, is a pangenotypic inhibitor of the HCV NS5A protein. NS5A is a multifunctional viral phosphoprotein critical for HCV RNA replication, virion assembly, and interaction with host cellular pathways. By inhibiting NS5A, velpatasvir disrupts key stages of the viral life cycle, including replication complex formation and viral particle production. The co-formulation of these two agents provides a potent, complementary antiviral activity, leading to a high barrier to resistance and profound reductions in viral load, resulting in high sustained virologic response rates across all HCV genotypes. This dual-target mechanism minimizes the potential for treatment failure due to emergent resistance mutations.